Single Mouse Preclinical Trial (SMPT): a tool for translational research
Authors :
C. MIGNARD, M. HILLAIRET DE BOISFERON, F. BICHAT, D. FRANCE, O. DUCHAMP, P. SLOS
Introduction :
Roughly, 85% of preclinical drug candidates entering oncology clinical trials fail to demonstrate sufficient safety or efficacy to gain regulatory approval. Hence, there is a need for experimental systems which better mimic the inter-patient response heterogeneity observed in the clinic. Patient-derived tumor xenograft (PDX) mouse models have emerged as a relevant oncology research tool to study tumor evolution, drug response, biomarkers, resistance phenomenon and personalized reatments to each patient.
Oncodesign PDX Surrogate Clinical Trial
We will here expose the effectiveness of the Single Mouse Preclinical Trial (SMPT) paradigm for evaluating drug response, as mono or combo therapy using our well-characterized PDX collection. Based on the “1 PDX tumor/1 mouse/1 treatment” experimental design, a cohort of colorectal and breast PDX models was used to explore response to Standard Of Care (SOC) and combo therapy used in clinic.